VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update

VivoSim Labs, Inc. (NASDAQ:VIVS) was the target of a significant drop in short interest in June. As of June 15th, there was short interest totaling 19,972 shares, a drop of 40.1% from the May 31st total of 33,344 shares. Approximately 0.8% of the company’s shares are short sold. Based on an average trading volume of 58,969 shares, the short-interest ratio is presently 0.3 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP purchased a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs at the end of the most recent reporting period. 8.23% of the stock is owned by institutional investors.

VivoSim Labs Stock Down 7.5%

Shares of NASDAQ:VIVS opened at $0.98 on Friday. The firm has a fifty day moving average of $1.26 and a two-hundred day moving average of $1.67. VivoSim Labs has a 12-month low of $0.94 and a 12-month high of $5.30. The firm has a market capitalization of $2.56 million, a P/E ratio of -0.31 and a beta of 1.40.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.